Miriam Erlacher

This study identifies specific mutational sequences in congenital neutropenia patients that predict leukemic transformation.

The paper develops a hierarchical classification framework combining epigenetic and genetic data with machine learning to improve diagnosis and risk stratification in hematologic malignancies.

This study shows that TET2 loss increases lymphoma penetrance and promotes survival of premalignant B cells in MYC-driven lymphoma by reducing apoptosis.

This study identifies oncofetal reprogramming in juvenile myelomonocytic leukemia, linking RAS-pathway activation to fetal gene expression and revealing CD52 as a therapeutic target.

This study identifies PTPN11/SHP2-driven adenosine signaling as a mechanism of immune escape in JMML, showing that CD39 inhibition can enhance T cell responses and reduce myeloproliferation.

This study shows AURKA promotes neuroblastoma malignancy and is suppressed by the PP2A pathway, with AURKA cooperating with MYCN in tumor progression.

This study shows that GATA2 deficiency leads to hematological issues through bone marrow failure and maladaptation, with leukemia arising from genomic instability and proliferation defects.

This study shows that CHK1 is essential for hematopoietic stem cell survival and fetal hematopoiesis, and that its inhibition causes severe DNA damage and prevents HSC expansion.